Coyle's research could have far-reaching applications, from expanding the scope of cell-based therapies to fight disease to developing micro-technologies for bioremediation of damaged environmental sites.
The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma.
Chris Bradfield, a UW–Madison Professor of Oncology, has been named the new director of the Biotechnology Center. Bradfield had been serving as the center’s…
When Kaivalya Molugu was considering graduate schools, she knew she was interested in stem cell research, but she had to decide where to apply. The answer soon became clear: the place where it all began.
Mike Sussman, longtime director of the UW–Madison Biotechnology Center, has announced that he is stepping down from that position to serve as director of the genome center. Chris Bradfield has been named interim Biotechnology Center director.
Speakers at the annual Wisconsin Stem Cell Symposium will discuss clinical trials involving stem cells, safety considerations and the regulatory environment under which ongoing stem cell work takes place.
This summer, in a unique collaboration, a team from the University of Wisconsin–Madison recovered wreckage and possible human remains from a site in France where an American pilot crashed during World War II.
The study provided a level of detail not available even five years ago. Improved technology cut the time to analyze all the proteins in a yeast sample from four hours to one hour.
A Madison lab is using the university's quick response manufacturing techniques to bring products to market more quickly and improve profits.
"We get two for the price of one," says researcher Shannon Stahl, "and we can save half a volt ... In a fuel cell, that is significant saving of energy."
The company makes cutting-edge products based on discoveries by three UW scientists for delivering DNA and RNA into cells.
Lynx Biosciences is developing technology to choose the drug most likely to benefit a blood cancer patient by analyzing how the tumor cells respond.
Unlike many young biotech spinoffs, Fritz Schomburg's company — Lytic — earns its income not from federal research grants, but from shipping product.